Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 210

1.

Macrophage Overexpressing NGAL Ameliorated Kidney Fibrosis in the UUO Mice Model.

Guiteras R, Sola A, Flaquer M, Hotter G, Torras J, Grinyó JM, Cruzado JM.

Cell Physiol Biochem. 2017 Aug 9;42(5):1945-1960. doi: 10.1159/000479835. [Epub ahead of print]

2.

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.

Lloberas N, Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM.

Pharmacogenet Genomics. 2017 Sep;27(9):313-322. doi: 10.1097/FPC.0000000000000296.

PMID:
28704257
3.

Posttransplant Lymphoproliferative Disease and Inhibitors of Mammalian Target of Rapamycin: When a Quick Look Back Can Change the Perspective.

Castillo-Eraso L, Melilli E, Cabre C, Manonelles A, Landeyro J, Bestard O, Cruzado JM, Martinez-Vea A.

Exp Clin Transplant. 2017 Jun 28. doi: 10.6002/ect.2016.0261. [Epub ahead of print]

4.

Looking for the needle in the kidney transplantation haystack.

Cruzado JM, Melilli E.

Clin Kidney J. 2017 Feb;10(1):95-96. doi: 10.1093/ckj/sfw122. Epub 2017 Jan 7.

5.

Corrigendum to 'Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients' [Clinica Chimica Acta (2017) 61-67].

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Clin Chim Acta. 2017 Aug;471:94. doi: 10.1016/j.cca.2017.05.024. Epub 2017 May 24. No abstract available.

PMID:
28550742
6.

Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.

Crespo E, Fernandez L, Lúcia M, Melilli E, Lauzurica R, Penin RM, Quer A, Luque S, Quero M, Manonelles A, Torras J, Cruzado JM, Cañas L, Grinyó JM, Bestard O.

Transplantation. 2017 Apr 11. doi: 10.1097/TP.0000000000001759. [Epub ahead of print]

PMID:
28403126
7.

Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study.

Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K; ELEVATE Study Group.

Transplantation. 2017 Mar 22. doi: 10.1097/TP.0000000000001739. [Epub ahead of print]

PMID:
28333860
8.

Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.

Crespo E, Cravedi P, Martorell J, Luque S, Melilli E, Cruzado JM, Jarque M, Meneghini M, Manonelles A, Donadei C, Lloberas N, Gomà M, Grinyó JM, Heeger P, Bestard O.

Kidney Int. 2017 Jul;92(1):201-213. doi: 10.1016/j.kint.2016.12.024. Epub 2017 Mar 6.

PMID:
28274484
9.

Data on genotypic distribution and linkage disequilibrium of several ANRIL polymorphisms in hemodialysis patients.

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Data Brief. 2017 Feb 12;11:221-224. doi: 10.1016/j.dib.2017.02.011. eCollection 2017 Apr.

10.

[Lesions Detected in Six Spanish Colorectal Cancer Screening Population Based Programmes. CRIBEA Project. Spain].

Portillo Villares I, Arana-Arri E, Idigoras Rubio I, Espinás Piñol JA, Pérez Riquelme F, de la Vega Prieto M, González Aledo A, Oceja Setien E, Vanaclocha Espi M, Ibáñez Cabanell J, Salas Trejo D; Grupo CRIBEA.

Rev Esp Salud Publica. 2017 Feb 20;91. pii: e201701021. Spanish.

11.

Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients.

Arbiol-Roca A, Padró-Miquel A, Hueso M, Navarro E, Alía-Ramos P, González-Álvarez MT, Rama I, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

Clin Chim Acta. 2017 Mar;466:61-67. doi: 10.1016/j.cca.2016.12.029. Epub 2017 Jan 2.

PMID:
28057453
12.

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N.

Clin Pharmacokinet. 2017 Aug;56(8):963-975. doi: 10.1007/s40262-016-0491-3.

PMID:
28050888
13.

Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.

de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group.

Am J Transplant. 2017 Jul;17(7):1853-1867. doi: 10.1111/ajt.14186. Epub 2017 Feb 14.

PMID:
28027625
14.

Macrophage in chronic kidney disease.

Guiteras R, Flaquer M, Cruzado JM.

Clin Kidney J. 2016 Dec;9(6):765-771. Epub 2016 Oct 5. Review.

15.

Datasets for the validation of the "in vivo" siRNA-silencing of CD40 and for the detection of new markers of atherosclerosis progression in ApoE-deficient mice.

Hueso M, De Ramon L, Navarro E, Ripoll E, Cruzado JM, Grinyo JM, Torras J.

Data Brief. 2016 Nov 19;9:1105-1112. eCollection 2016 Dec.

16.

Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.

Hueso M, De Ramon L, Navarro E, Ripoll E, Cruzado JM, Grinyo JM, Torras J.

Atherosclerosis. 2016 Dec;255:80-89. doi: 10.1016/j.atherosclerosis.2016.11.002. Epub 2016 Nov 2.

PMID:
27835742
17.

Online Haemodiafiltration Improves Inflammatory State in Dialysis Patients: A Longitudinal Study.

Rama I, Llaudó I, Fontova P, Cerezo G, Soto C, Javierre C, Hueso M, Montero N, Martínez-Castelao A, Torras J, Grinyó JM, Cruzado JM, Lloberas N.

PLoS One. 2016 Oct 26;11(10):e0164969. doi: 10.1371/journal.pone.0164969. eCollection 2016.

18.

Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.

Cruzado JM, Pascual J, Sánchez-Fructuoso A, Serón D, Díaz JM, Rengel M, Oppenheimer F, Hernández D, Paravisini A, Saval N, Morales JM; Evita Study Group.

Transpl Int. 2016 Dec;29(12):1317-1328. doi: 10.1111/tri.12862. Epub 2016 Oct 17.

PMID:
27648523
19.

Decreased Kidney Graft Survival in Low Immunological Risk Patients Showing Inflammation in Normal Protocol Biopsies.

Ortiz F, Gelpi R, Helanterä I, Melilli E, Honkanen E, Bestard O, Grinyo JM, Cruzado JM.

PLoS One. 2016 Aug 17;11(8):e0159717. doi: 10.1371/journal.pone.0159717. eCollection 2016.

20.

Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis.

Draibe JB, Fulladosa X, Cruzado JM, Torras J, Salama AD.

Clin Kidney J. 2016 Aug;9(4):547-51. doi: 10.1093/ckj/sfw056. Epub 2016 Jun 29.

Supplemental Content

Loading ...
Support Center